Synergism of a novel MCL‑1 downregulator, acriflavine, with navitoclax (ABT‑263) in triple‑negative breast cancer, lung adenocarcinoma and glioblastoma multiforme-Reference-Cited by-同舟云学术

Synergism of a novel MCL‑1 downregulator, acriflavine, with navitoclax (ABT‑263) in triple‑negative breast cancer, lung adenocarcinoma and glioblastoma multiforme

Published:2021-12-08 Issue:1 Volume:60 Page:
ISSN:1019-6439
Container-title:International Journal of Oncology
language:
Short-container-title:Int J Oncol

Author:

Lee Anbok¹,Jin Hyeon-Ok²,Masudul Haque Md.³,Kim Hee¹,Jung Hana³,Park Jin³,Kim Ilwhan⁴,Song Joo⁵,Yoon Hye⁶,Kim Hyoung⁷,Han Jin⁷,Park In-Chul⁸,Kim Kwang⁸,Park Sae³

Affiliation:

1. Department of Surgery, Busan Paik Hospital, College of Medicine, Inje University, Busan 47392, Republic of Korea

2. KIRAMS Radiation Biobank, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Republic of Korea

3. Department of Microbiology and Immunology, College of Medicine, Inje University, Busan 47392, Republic of Korea

4. Department of Internal Medicine, Division of Oncology, Haeundae Paik Hospital, College of Medicine, Inje University, Busan 48108, Republic of Korea

5. Department of Pathology, Dongnam Institute of Radiological and Medical Sciences, Busan 46033, Republic of Korea

6. Department of Pathology, Inje University, Busan 47392, Republic of Korea

7. Cardiovascular and Metabolic Disease Center, Smart Marine Therapeutic Center, College of Medicine, Inje University, Busan 47397, Republic of Korea

8. Division of Radiation Biomedical Research, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Republic of Korea

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting Mitochondria with ClpP Agonists as a Novel Therapeutic Opportunity in Breast Cancer;Cancers;2023-03-23

2. Targeting Senescence as a Therapeutic Opportunity for Triple-Negative Breast Cancer;Molecular Cancer Therapeutics;2023-02-07

3. Mitochondrial targeting theranostic nanomedicine and molecular biomarkers for efficient cancer diagnosis and therapy;Biomedicine & Pharmacotherapy;2022-09

4. Acriflavine, an Acridine Derivative for Biomedical Application: Current State of the Art;Journal of Medicinal Chemistry;2022-08-26